Status:
UNKNOWN
EEG as Predictor of HD-tDCS Effectiveness in Long COVID-19
Lead Sponsor:
Federal University of Paraíba
Conditions:
Coronavirus COVID-19
Respiratory Infection
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
COVID-19 is an infectious disease which presents a heterogenous clinical presentation. Recent investigations suggest that people who were infected by COVID-19 often develop physical disabilities (i.e....
Detailed Description
A double-blinded randomized clinical trial will be carried to analyse the EEG as neurobiological predictor marker of HD-tDCS 4x1 in patients in long COVID-19. This study is in accordance with the CONS...
Eligibility Criteria
Inclusion
- Patients who had a medical diagnosis of COVID-19, clinically stable, able to respond to simple commands, able to walk for six minutes and who sign study consent form will be enrolled. Those who present associated neurological diseases, pregnant, users of psychoactive drugs, patients who have metallic implants, electronic devices, pacemakers, or epileptic patients will be excluded.
Exclusion
Key Trial Info
Start Date :
February 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05289128
Start Date
February 7 2022
End Date
July 31 2022
Last Update
March 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Federal University of Paraíba,Department of Psychology
João Pessoa, Paraíba, Brazil, 58051-900